Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.
BJU IntMay 12, 2026 (epub)
Nancy Wei, Ryan M Phillips, Eugene Kwon et al.
✦ AI-curated · Sources linked
In 30 seconds
The BRIO study is a randomized controlled trial investigating the management of biochemical recurrence (BCR) in men post-radical prostatectomy. It compares salvage radiotherapy (SRT) to observation in patients with PSA levels between 0.2 and 1.5 ng/mL and negative imaging results. The trial aims to enroll 312 patients to assess distant recurrence-free survival at 5 years.
Key findings
- The trial will enroll 312 patients with BCR after radical prostatectomy.
- Primary endpoint is distant recurrence-free survival at 5 years.
- Participants will be randomized 1:1 to SRT or observation.
- 30 metastasis events will provide 80% power to detect significant differences.
Why it matters
This study addresses a critical gap in managing BCR after prostatectomy, particularly in patients with negative imaging, potentially influencing treatment protocols and patient outcomes in urology and oncology.